To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
Luc Truyen
Chief Medical Officer
Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership positions, primarily within neuroscience. He has a strong track record in clinical development resulting in several global innovative drug approvals.
In his most recent position, Luc was global head of development for neuroscience at JNJ and managed the strategy and delivery of the early and late portfolio of assets for mood disorders, schizophrenia, and neurodegenerative and neuroinflammatory disorders.
His broad-based experience also includes leading global clinical development operations for the whole JNJ pharmaceutical group as well as serving as Head of R&D and CMO of Janssen Alzheimer Immunotherapy (JAI), an internal spin-out from JNJ. Luc holds an M.D. and Ph.D. in Neurology from the University of Antwerp.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Grants
Funding research, education, and initiatives that raise the standard of care.
About Us
Discover why we’re more than a unique name.
Newsroom
The latest news and press releases from argenx.
